Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Gemcitabine and Carboplatin in Elderly NSCLC
NCT00881296Phase 2Completed
- Sponsor
- Hamamatsu University School of Medicine
- Start
- Mar 2008
- Primary completion
- Mar 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hamamatsu University School of Medicine. Primary endpoint: Objective Response Rate at 2 years. Started Mar 2008; status: completed.
02
Drugs
carboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00881296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881296.